Next Generation Medicines Inspired by Nature

What we do

Flavocure

Flavocure Biotech Inc. aims to be a leader in transforming natural products into new cures for patients.

The company has discovered several promising new drug candidates. In collaboration with some of the most prestigious research institutions in the world, Flavocure is advancing these candidates through clinical research. Preliminary data indicate that Flavocure’s drug candidates possess activity against known driver mutations and targets implicated in cancer.

Caflanone is Flavocure’s lead drug candidate and received FDA Orphan Drug Designation in 2019 for pancreatic cancer. 

In addition to pancreatic cancer, Flavocure’s drug candidates have demonstrated activity in a variety of cancers, including Glioblastoma (an aggressive form of brain cancer), Acute Myeloid Leukemia, and Multiple Myeloma.

Flavocure Biotech

Oncology Pipeline

Product
Target
Disease
Developmental Stage
Worldwide Rights
Research Partners
Caflanone
CSF1R
Pancreatic Cancer
IND ready
FDA-ORPHAN Drug Designation
new logo1
Ongoing
Caflanone
CSF1R
GBM/Myeloma
Pre-Clinical
new logo1
Ongoing
Cresorol
FLT3
AML
FDA-ORPHAN Drug Designation
new logo1
Ongoing

In the US, SEER reported pancreatic cancer as the 11th most common cancer with 60,430 new cases and 48,220 deaths in 2022. Pancreatic cancer statistics highlight a dire need for transformative therapies for this lethal disease

2022 US Pancreatic Cancer Statistics

Our Team

Henry Lowe PhD

Henry C. Lowe, PhD

Executive Chairman/Founder/Director
Ngeh Toyang PhD

Ngeh J. Toyang, PhD

CEO/Co-Founder/Director
justin grant

Justin Grant, PhD

Director

Media

Latest News

Newsletter

Subscribe to Receive News from Flavocure Biotech

Join our Mailing list!

Get all latest news from Flavocure Biotech